PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy

PURPOSE: There remain a lack of biomarkers for endocrine therapy resistance in patients with breast cancer (BC), which is proving to be a great challenge. In vitro experiments have shown that downregulation of PTEN expression leads to resistance to tamoxifen (TAM) in BC cells. We aimed to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yu, Xie, Guiqin, Wang, Zhu, Wang, Yu, Wang, Yanping, Zheng, Hong, Zhong, Xiaorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841328/
https://www.ncbi.nlm.nih.gov/pubmed/34978016
http://dx.doi.org/10.1007/s10549-021-06463-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841328/
https://www.ncbi.nlm.nih.gov/pubmed/34978016
http://dx.doi.org/10.1007/s10549-021-06463-6

Ejemplares similares